Damora Therapeutics Ownership | Who Owns Damora Therapeutics?
Damora Therapeutics Ownership Summary
Damora Therapeutics is owned by 107.30% institutional investors, 7.60% insiders. Marshall wace, llp is the largest institutional shareholder, holding 0% of DMRA shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 4.10% of its assets in Damora Therapeutics shares.
DMRA Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Damora Therapeutics | 107.30% | 7.60% | -14.90% |
| Sector | Healthcare Stocks | 245.07% | 12.10% | -157.17% |
| Industry | Biotech Stocks | 380.48% | 11.73% | -292.21% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Marshall wace, llp | - | - | - |
| Jane street group | - | - | - |
| Harbour investments | - | - | - |
| Boothbay fund management | - | - | - |
| Millennium management | - | - | - |
| Landscape capital management | - | - | - |
| Brevan howard capital management lp | - | - | - |
| Schonfeld strategic advisors | - | - | - |
| Hudson bay capital management lp | - | - | - |
| Y-intercept (hong kong) | - | - | - |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Marshall wace, llp | - | - | - |
| Jane street group | - | - | - |
| Harbour investments | - | - | - |
| Boothbay fund management | - | - | - |
| Millennium management | - | - | - |
| Landscape capital management | - | - | - |
| Brevan howard capital management lp | - | - | - |
| Schonfeld strategic advisors | - | - | - |
| Hudson bay capital management lp | - | - | - |
| Y-intercept (hong kong) | - | - | - |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Harbour investments | - | - | -40.00 |
| Y-intercept (hong kong) | - | - | -7.92K |
| Cannon global investment management | - | - | -9.30K |
| Schonfeld strategic advisors | - | - | -10.82K |
| Jane street group | - | - | -11.42K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Millennium management | - | - | -471.65K |
| Qube research | - | - | -282.44K |
| Marshall wace, llp | - | - | -169.82K |
| Boothbay fund management | - | - | -110.44K |
| Hudson bay capital management lp | - | - | -76.34K |
Sold Out
| Holder | Change |
|---|---|
| Harbour investments | -40.00 |
| Y-intercept (hong kong) | -7.92K |
| Cannon global investment management | -9.30K |
| Schonfeld strategic advisors | -10.82K |
| Jane street group | -11.42K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | 103 | 60.94% | 65,599,086 | 17.15% | 107 | 0.40% | 79 | 25.40% | 9 | - |
| Mar 31, 2026 | 64 | 255.56% | 55,997,999 | 4954.52% | 163 | 2.34% | 63 | 320.00% | - | -100.00% |
| Dec 31, 2025 | 18 | 50.00% | 1,107,880 | 550.91% | 83 | 50.75% | 15 | 114.29% | 3 | - |
| Sep 30, 2025 | 12 | 33.33% | 170,205 | 28.20% | 12 | 12.73% | 7 | 133.33% | 3 | -25.00% |
| Jun 30, 2025 | 9 | -18.18% | 132,760 | -6.97% | 10 | 8.62% | 3 | -40.00% | 4 | 300.00% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 2.53M | 4.10% | 220.00 |
| Fidelity Growth Company Fund | 1.83M | 2.96% | -2.26K |
| iShares Russell 2000 ETF | 1.34M | 2.16% | -23.71K |
| Fidelity Small Cap Growth | 834.04K | 1.35% | - |
| JPMorgan Small Cap Growth A | 741.35K | 1.20% | 230.04K |
| State Street® SPDR® S&P® Biotech ETF | 703.85K | 1.14% | 1.61K |
| Fidelity Growth Company K6 | 537.65K | 0.87% | 2.26K |
| Fidelity Select Health Care | 500.00K | 0.81% | - |
| Fidelity Select Biotechnology | 454.56K | 0.74% | - |
| Fidelity Series Growth Company | 452.81K | 0.73% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Sep 25, 2026 | Jarrett Jennifer | Director, President and CEO | Buy | $252.88K |
| Jul 06, 2026 | Winslow Garrett | General Counsel | Sell | $7.35K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q3 | - | 1 |
| 2026 Q2 | - | - |
| 2026 Q1 | - | - |
DMRA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools